Baxter International Inc (BAX)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $13.35B
Last updated: Nov 17, 2026 at 11:05 AM ET
Baxter International Inc (BAX) Financials: Revenue, Profit and Cash Flow
Baxter International reported revenue of $11.24B for the fiscal year ended Dec 31, 2025, up 5.7% from the year before. That year, net income was -$957.00M with a net margin of -8.5%, operating cash flow was $845.00M and free cash flow was $332.00M. The quarter ended Sep 30, 2026 had revenue of $2.98B and net income of $294.00M.
Revenue and Margins
The operating margin was -2.7% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $10.16B, a compound annual rate of 1.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $11.24B | +5.7% | 30.1% | -2.7% | -8.5% |
| Dec 2024 | $10.64B | +2.7% | 37.5% | 0.1% | -6.0% |
| Dec 2023 | $10.36B | +3.0% | 40.1% | 6.8% | 25.7% |
| Dec 2022 | $10.06B | -17.2% | 35.3% | -28.3% | -24.1% |
| Dec 2021 | $12.15B | +4.1% | 38.9% | 11.1% | 10.7% |
| Dec 2020 | $11.67B | +2.7% | 39.3% | 13.8% | 9.5% |
| Dec 2019 | $11.36B | +2.4% | 41.9% | 15.6% | 8.9% |
| Dec 2018 | $11.10B | +4.9% | 42.9% | 14.3% | 13.9% |
| Dec 2017 | $10.58B | +4.1% | 42.3% | 12.2% | 5.7% |
| Dec 2016 | $10.16B | N/A | 40.5% | 7.3% | 48.9% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.24B | $10.64B | $10.36B | $10.06B | $12.15B | $11.67B | $11.36B | $11.10B | $10.58B | $10.16B |
| Cost of revenue | $7.87B | $6.65B | $6.21B | $6.51B | $7.43B | $7.09B | $6.60B | $6.34B | $6.11B | $6.05B |
| Gross profit | $3.38B | $3.98B | $4.15B | $3.55B | $4.72B | $4.59B | $4.76B | $4.76B | $4.47B | $4.12B |
| Research and development | $518.00M | $590.00M | $518.00M | $450.00M | $531.00M | $521.00M | $595.00M | $654.00M | $615.00M | $646.00M |
| Operating income | -$308.00M | $14.00M | $707.00M | -$2.85B | $1.35B | $1.62B | $1.77B | $1.58B | $1.29B | $745.00M |
| Net income | -$957.00M | -$638.00M | $2.66B | -$2.42B | $1.29B | $1.11B | $1.01B | $1.55B | $602.00M | $4.96B |
| EBITDA | $714.00M | $1.05B | $1.67B | -$1.78B | $2.18B | $2.25B | $1.83B | $2.43B | $1.91B | $5.82B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.98B | $2.96B | $2.70B | $2.97B | $2.83B | $2.81B | $2.63B | $2.75B | $2.70B | $2.69B | $2.49B | $541.00M |
| Gross profit | $994.00M | $1.03B | $891.00M | $577.00M | $950.00M | $991.00M | $861.00M | $959.00M | $1.03B | $1.03B | $961.00M | $708.00M |
| Operating income | $225.00M | $217.00M | $66.00M | -$729.00M | $172.00M | $191.00M | $58.00M | -$435.00M | $155.00M | $179.00M | $115.00M | $416.00M |
| Net income | $294.00M | $126.00M | -$15.00M | -$1.13B | -$46.00M | $91.00M | $126.00M | -$510.00M | $144.00M | -$311.00M | $39.00M | $246.00M |
Balance Sheet
As of Dec 2025, total debt of $9.48B exceeded cash and equivalents by $7.51B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $20.05B | $25.78B | $28.28B | $28.29B | $33.52B | $20.02B | $18.19B | $15.72B | $17.11B | $15.55B |
| Current assets | $6.87B | $8.85B | $9.60B | $8.01B | $8.87B | $8.41B | $7.50B | $5.96B | $7.26B | $6.57B |
| Cash and equivalents | $1.97B | $1.76B | $3.08B | $1.72B | $2.95B | $3.73B | $3.33B | $1.84B | $3.39B | $2.80B |
| Total liabilities | $13.95B | $18.76B | $19.81B | $22.39B | $24.40B | $11.29B | $10.28B | $7.85B | $8.00B | $7.27B |
| Short-term debt | $3.00M | $2.75B | $2.67B | $1.40B | $511.00M | $406.00M | $541.00M | $4.00M | $3.00M | $3.00M |
| Long-term debt | $9.47B | $10.37B | $11.09B | $15.23B | $17.15B | $5.79B | $4.81B | $3.48B | $3.51B | $2.78B |
| Shareholder equity | $6.13B | $6.96B | $8.40B | $5.83B | $9.08B | $8.69B | $7.88B | $7.84B | $9.12B | $8.29B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $19.41B | $19.79B | $19.85B | $20.05B | $21.07B | $21.05B | $21.30B | $25.78B | $26.68B | $26.31B | $27.79B | $28.28B |
| Total liabilities | $12.94B | $13.61B | $13.83B | $13.95B | $13.85B | $13.75B | $14.25B | $18.76B | $18.73B | $18.60B | $19.55B | $19.81B |
| Cash and equivalents | $1.98B | $2.15B | $2.02B | $1.97B | $1.73B | $1.69B | $2.29B | $1.76B | $1.42B | $2.10B | $3.03B | $3.08B |
| Shareholder equity | $6.50B | $6.21B | $6.04B | $6.13B | $7.24B | $7.32B | $7.08B | $6.96B | $7.87B | $7.64B | $8.17B | $8.40B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 39.3% of operating cash flow. Dividends came to 104.8% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $845.00M | $1.02B | $1.73B | $1.21B | $2.22B | $1.87B | $2.10B | $2.02B | $1.71B | $1.65B |
| Capital expenditures | $513.00M | $446.00M | $432.00M | $377.00M | $691.00M | $709.00M | $696.00M | $659.00M | $616.00M | $719.00M |
| Free cash flow | $332.00M | $573.00M | $1.29B | $834.00M | $1.53B | $1.16B | $1.41B | $1.36B | $1.10B | $935.00M |
| Dividends paid | $348.00M | $590.00M | $586.00M | $573.00M | $530.00M | $473.00M | $423.00M | $376.00M | $315.00M | $268.00M |
| Share repurchases | N/A | N/A | N/A | $32.00M | $600.00M | $500.00M | $1.27B | $2.45B | $564.00M | $292.00M |
| Investing cash flow | $2.84B | -$626.00M | $3.21B | -$931.00M | -$11.20B | -$1.18B | -$1.10B | -$916.00M | -$1.29B | -$715.00M |
| Financing cash flow | -$4.22B | -$1.08B | -$3.49B | -$1.44B | $8.24B | -$345.00M | $498.00M | -$2.60B | $93.00M | -$324.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $558.00M | $285.00M | $213.00M | $584.00M | $237.00M | $217.00M | -$193.00M | $488.00M | $253.00M | $115.00M | $163.00M | $531.00M |
| Capital expenditures | $110.00M | $116.00M | $137.00M | $140.00M | $111.00M | $140.00M | $122.00M | $132.00M | $134.00M | $70.00M | $110.00M | $92.00M |
| Free cash flow | $448.00M | $169.00M | $76.00M | $444.00M | $126.00M | $77.00M | -$315.00M | $356.00M | $119.00M | $45.00M | $53.00M | $439.00M |
Frequently Asked Questions About BAX
What is Baxter International's annual revenue?
Baxter International reported revenue of $11.24B for the fiscal year ended Dec 31, 2025.
How fast is Baxter International's revenue growing?
Revenue was up 5.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 3.8%.
Is Baxter International profitable?
No. Baxter International reported net income of -$957.00M for the fiscal year ended Dec 31, 2025, with a net margin of -8.5%.
How much free cash flow does BAX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $845.00M minus capital expenditures of $513.00M produced free cash flow of $332.00M.
How much debt does Baxter International have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $9.47B, short-term debt of $3.00M and cash and equivalents of $1.97B.
BAX pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors